Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest and Sustained Ventricular Arrhythmias.
Feb 20, 2025DOI: 10.1161/circep.124.013099Journal ArticleAHA
Written by: Apurba ChakrabartiJohn R GiudicessiFatima M EzzeddineFrancesca N DellingShalini DixitYoo Jin LeeDaniele MuserSilvia MagnaniAniek Van WijngaardenNina Ajmone MarsanMarc A MillerJonathan GandhiMaria G TrivieriJonaz FontRaphael MartinsJames A McCaffreyPasquale SantangeliFrancis E MarchlinskiHimal ChapagainDon MathewKrishna KancharlaFaisal F SyedAhad AbidLukasz CerbinWendy S TzouLohit GargDomenico G Della RoccaAndrea NataleSanghamitra MohantySeth H SheldonLing KuoKristina H HaugaaEivind W AabelAndres EnriquezShingo MaedaAmrish DeshmukhMichael GhannamFrank BogunMichael J AckermanJackson J Liang
Find these authors on Roon
FM
Dr. Francis Marchlinski
EP · HUP
AE
Dr. Andres Enriquez
EP · HUP
METHODS
Patients with MVP and SCA were retrospectively identified at 20 international centers. MVP was defined according to the standard definition, with ≥2 mm of displacement of the MV leaflets into the left atrium during systole by transthoracic cardiac imaging.19 Ventricular arrhythmias (VAs) included unexplained SCA or documented sustained monomorphic VT, polymorphic VT, or VF. VAs were attributed to MVP after evaluation excluding other known causes. Patients with cardiomyopathy unrelated to MVP, arrhythmic syndromes, channelopathies, or prior myocardial infarction were excluded. The study was approved by the institutional review board of the coordinating center (University of Michigan). The deidentified data that support the findings of this study are available from the first author upon reasonable request.Deidentified data were collected retrospectively at the individual institutional level into a standardized worksheet and deidentified data were transmitted to a central database for analysis. Data abstracted included baseline demographics, clinical comorbidities and medications, presence of cardiac implantable electronic devices, electrocardiography, echocardiography, ambulatory cardiac monitoring, and CMR. We also examined findings from invasive testing and treatment when performed, including electrophysiology studies, catheter ablation procedures, and cardiac surgery. Testing procedures were done according to local institutional protocols and were not standardized across the cohort. Not all patients had all types of imaging or testing.For analysis, inferolateral TWI was defined as TWI in at least two of the following leads: II, III, aVF, I, and aVL. Anterolateral TWI was defined as inversions in leads V5 or V6. A Barlow morphology valve was defined as those with bileaflet prolapse with leaflets at least 5 mm in thickness. The grading of mitral regurgitation was determined based on local institutional practice. MAD was defined as measurable systolic separation of the MV leaflet insertion point from the basal LV myocardium with excursion into the left atrium.Continuous variables were reported as mean±SD and compared using Student t test. Categorical variables were reported as percentages and compared using χ2 tests. If any analysis group included fewer than 25 patients and failed a Shapiro-Wilk normality test, we utilized nonparametric tests, including the Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables. Statistical comparisons were completed using STATA, version 14.2 (College Station, TX).
RESULTS
We identified 148 patients with prior SCA, sustained VT, or VF across 20 institutions (Table 1). Specifically, 96 (64.9%) patients had SCA, 43 (29.1%) had monomorphic VT, 23 (15.5%) had polymorphic VT, 75 (50.7%) had VF, and 8 (5.4%) had electrical storm (Figure 1). Some patients had >1 VA. Overall, most patients were young (43.7±15.4 years) and female gender (n=100, 67.6%).Prior MV repair/replacement was infrequent overall (n=8, 5.5%). β-blocker prescriptions were uncommon (n=51, 35.7%), and only a minority of patients were prescribed antiarrhythmic drugs (n=28, 20.1%).Combined data from echocardiography and CMR imaging showed that of the 141 patients with data on prolapsed leaflets, bileaflet prolapse was present in 103 (73.1%) patients. A smaller subset of 108 (73.0%) patients had data on MV leaflet thickness and morphology. Of those 108 patients, 73 (67.6%). Less than half of patients had moderate or worse MV regurgitation (Table 2). Characteristics significantly different between patients with mild or absent MV regurgitation versus moderate-severe MV regurgitation are shown in Table S1. MAD (from either echocardiography or CMR) was present in 82 (55.4% patients; Figure 2B).Historical data about the presence of symptoms associated with the AMVPS were available in 113 (76.4%) patients (Table 1). Syncope was common (n=54, 47.8%). Palpitations were seen in 63 (55.8%) patients. Only a minority of patients had symptoms of chest pain, near syncope, dyspnea, fatigue, or anxiety.In the 116 patients (78.4%) where detailed electrocardiography data was available, the mean corrected QT interval was 438±24 ms (Table 3). Inferolateral TWIs were common (n=69 [59.5%]). While anterolateral TWIs were less frequent than inferolateral TWIs, they were relatively frequent (n=26, 22.4%).Eighty-two patients (55.4%) had detailed data from ambulatory cardiac monitoring (Table 3). PVCs were common with a mean burden of 6.3±7.0%. Most patients had PVCs with a right bundle branch (Figure 2A) morphology (n=49, 87.5%). Most patients had at least 1 episode of nonsustained VT (n=72, 67.3%).One hundred twenty-one patients (81.8%) had detailed data from echocardiography available (Table 2). Overall, most patients had normal LV ejection fraction and LV size but did have left atrial dilation. 23 (48.6%) had data on the presence of Picklehaube sign.20,21 23 (31.9%) had the Picklehuabe sign.Fifty patients (33.8%) had detailed contrast enhanced CMR data available (Table 2). Six (12.0%) patients had delayed enhancement (DE) involving either the anterolateral or posteromedial papillary muscles. More patients had DE of either inferior (n=9, 18.0%) or inferolateral (n=14, 28.0%) LV myocardium. Twenty-eight (54.9%) had at least 1 area of DE. In our cohort, 64 (43.2%) patients had information on presence of inferior or inferolateral DE on CMR and TWI on surface electrocardiography. A total of 22/64 (34.4%) patients had DE in the inferior or inferolateral LV myocardium. Of these 19/22 (86.4%) patients had inferolateral TWI and only 3/22 (13.6%) had DE but no corresponding inferolateral TWI (P=0.003).A total of 45 patients underwent an electrophysiology study (EPS) with programmed ventricular stimulation (Table 4). In these survivors of SCA, 15/45 (33.3%) were noninducible during an EPS despite a prior sustained ventricular arrhythmia event. Of those with a negative EPS, 6/15 had prior monomorphic VT, 1/15 had polymorphic VT, 7/15 had VF, and one had an unknown arrhythmia inciting SCA.After the index event, MV repair/replacement was performed in a minority of patients (n=11 [7.8%], Table 4). Implantable cardiac defibrillators were placed after the index event in most patients (n=128, 87.1%),PVC ablation was performed in 50 (35%) patients (Table 4). Of the 50 patients who underwent PVC ablation, the most common sites of origin for PVCs (Figure 3A) were the posteromedial papillary muscle (n=25), anterolateral papillary muscle (n=19), mitral annulus (n=6, Figure 2C), LV inferolateral wall (n=5), fascicles (n=4), LV septum (n=5), LV inferior wall (n=5), LV outflow tract (n=4), right ventricular outflow tract (n=4), or LV anterolateral wall (n=1). VT ablation was performed in a minority of patients (Table 4). Sites of origin for VTs (Figure 3B) included posteromedial papillary muscle (n=6), fascicles (n=4), mitral annulus (n=5), anterolateral papillary muscle (n=3), LV inferolateral wall (n=3), LV inferior wall (n=3), right ventricular source (n=1), and LV anterolateral wall (n=1). Each subject may have had >1 focus of PVC or VTs.
DISCUSSION
This study represents the largest multicenter series characterizing patients with AMVPS at the highest arrhythmic risk, including those surviving SCA. This cohort of 148 patients included 96 (65%) patients with SCA and 52 (35%) patients with sustained VT/VF. This study expands upon the initial comprehensive description of AMVPS that stemmed from an analysis of 10 of 24 SCA survivors with structurally normal hearts who had bileaflet MVP, where the key components of AMVPS were defined.9 In contrast, the largest previous case series examining AMVPS included 295 patients with some VAs, but only 10 (3.3%) patients were SCA survivors.10 Other larger studies include larger samples of patients with MVP but only small samples of patients with SCA or clinically significant VAs. One systematic review did include 123 patients with MVP and SCA, but included studies spanned 50 years, making interpretation of the findings difficult.22 In our study, all patients had significant arrhythmias, either surviving SCA or sustained VT/VF. Most included patients met multiple arrhythmia risk criteria (eg, nonsustained VT, bigeminal PVCs, MAD, bileaflet MVP).In general, our registry phenotypically characterizes patients with SCA survivors with AMVPS as typically young, female gender, with bileaflet prolapse and MAD (Figure 4). Over half had mild or less mitral regurgitation. Cardiac monitoring shows frequent inferolateral TWIs, frequent PVCs (average 7.0%), typically with right bundle branch morphology, often with PVC bigeminy and nonsustained VT. Forty-five percent of patients had some DE on CMR, but only a minority had papillary muscle DE in our study. These characteristics have also been previously documented in prior studies and meta-analyses, although with some variability due to heterogeneous study populations.3,7,9,11,12,15,16,22–25Our patients were predominantly women and younger in age, which has been seen in most studies enriched with patients with MVP with SCA.7,9,23,26,27 In other studies with a lower proportion of patients with SCA, the average age was higher, and a greater proportion of men were seen.16,28 It is possible that the population at the highest risk of SCA is younger and women, although not all autopsy studies have shown a women or younger age predominance.8Our study includes one of the largest descriptions of AMVPS undergoing invasive catheter ablation. Similar to prior studies,14,23 areas associated with the MV apparatus (papillary muscles, mitral annulus, inferior/inferolateral LV), as well as the conduction system/fascicular system, were the most common sites of origin for both PVCs and VT. It is worth noting, though, that it was not rare in our study to have other non-MV or conduction system sources including outflow tracts, the right ventricular, and other locations.The existence of a symptom complex associated with MVP is controversial. In our study, a history of syncope was common in the survivors of SCA, while symptoms such as chest pain and palpitations were not common. This suggests that particular attention should be placed on patients with MVP with syncope compatible with an arrhythmic etiology. These patients may warrant further testing. This is consistent with prior work and the published expert consensus statement.22,29,30Several studies have shown inferolateral TWIs associated with AMVPS, and in our population over half of the patients had inferolateral TWIs.7,16,18 A novel finding in the current study was that anterolateral TWIs (involving precordial leads V5 or V6), while significantly less prevalent overall, were relatively frequent among patients with SCA. Anterolateral TWIs were not associated with anterolateral DE on CMR in our study. In contrast, the presence of DE in the LV inferior or inferolateral myocardium was associated with the presence of inferolateral TWIs. This lends credence to the hypothesis that cardiac fibrosis leads to repolarization abnormalities in the corresponding myocardium and may contribute to electrical instability and arrhythmogenesis. Other studies have confirmed that more diffuse TWIs on electrocardiography are associated with cardiac fibrosis and arrhythmic risk.31EPS are performed in a wide variety of patient groups to help stratify the risk of VAs. The predictive validity of EPS in patients diagnosed with AMVPS is not well documented. In this series, one-third of patients who survived SCA still had a negative EPS. While this finding is hypothesis-generating, our study cannot evaluate the negative or positive predictive value of EPS due to a lack of quantified follow-up time, the possibility that survivors of SCA may have undergone EPS with different stimulation protocols if EPS was done during catheter ablation, EPS may have been done with or without an antiarrhythmic drug holiday, and varying utilization of conscious sedation versus general anesthesia. Most centers currently perform EPS with programmed ventricular stimulation from one or two right ventricular sites. However, given the possibility of site specificity for programmed ventricular stimulation, since the arrhythmia substrates in MVP-SCA are predominantly in the LV, programmed stimulation from both the right and left ventricles may increase the predictive value of EPS. Our series did not include data on the sites of stimulation during EPS, the presence of AAD at the time of EPS, or the sedation used during EPS.Our study has several important limitations. First, due to its retrospective and cross-sectional nature, causality cannot be inferred. Since follow-up time after SCA was not quantified, accurate conclusions about long-term characteristics and predictive accuracy cannot be drawn. Due to significant survivorship bias in survivors of SCA, only limited conclusions can be drawn about the overall population of AMVPS. Due to the multicenter design, there was variable work-up performed and access to records; many patients did not have all forms of testing. Missing data could introduce bias. In addition, the performance and interpretation of testing, imaging, and treatment could not be standardized. Since our series did not have a control group of low- or average-risk in patients with MVP, we are unable to specifically identify risk factors that delineate patients at low and high risk of arrhythmias.
CONCLUSIONS
In this large international descriptive registry, patients with arrhythmogenic MV prolapse syndrome were young, women, and typically had bileaflet MVP, MAD, inferolateral TWIs, nonsustained VT, and frequent PVCs, often with PVC bigeminy. Less than half of the patients had abnormal DE on CMR. A history of syncope and anterolateral TWIs were relatively frequent novel findings in patients who survived SCA or sustained VT/VF.